

## NABP's Programs Featured in Newest Documentary

From NABP &lt;news@nabp.pharmacy&gt;

Date Wed 3/25/2026 7:31 PM

To Barron, Karin (DOH) &lt;karin.barron@dc.gov&gt;

**CAUTION:** This email originated from outside of the DC Government. Do not click on links or open attachments unless you recognize the sender and know that the content is safe. If you believe that this email is suspicious, please forward to phishing@dc.gov for additional analysis by OCTO Security Operations Center (SOC).



## NABP Featured in *Strengthening the Pharmacy Supply Chain to Keep Patients Safe* Documentary

From identifying legitimate online pharmacies to connecting members of the drug supply chain, NABP's programs are designed to safeguard the public domestically and globally to ensure that consumers are receiving verified, legitimate prescription medications. The recently debuted documentary, *Strengthening the Pharmacy Supply Chain to Keep Patients Safe*, spotlights NABP's various programs and resources, such as Healthcare Merchant Accreditation, the Safe Pharmacy website, and Pulse by NABP™, as well as other ongoing pilot projects like Operation African Star 2. The documentary also features a real-world case where NABP's Pulse Product Verification Service, a component of Pulse by NABP, helped the boards of pharmacy detect a suspect prescription product.

[Watch the Video](#)

## DEA Issues Temporary Order for Bromazolam, Synthetic Benzodiazepine

**Drug Enforcement Administration (DEA)** has issued a temporary order to place bromazolam, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible, in Schedule I of the Controlled Substances Act.

Bromazolam, a synthetic compound, has been one of the most frequently reported benzodiazepines found in drug seizures, according to the agency. The novel psychoactive substance has been associated with adverse health effects, such as ataxia, altered mental state, respiratory depression, and slurred speech, which have been linked to effects of certain drugs labeled as "designer benzodiazepines." DEA's notice is effective from March 16, 2026, until March 16, 2028.

[Read DEA's Notice on Bromazolam](#)

## ISMP Develops Risk-Reduction Strategies Factoring in Human and System Reliability

The Institute for Safe Medication Practices (ISMP) has developed its Hierarchy of Effectiveness of Risk-Reduction Strategies, which is centered on error prevention. The model is categorized into high-

leverage, medium-leverage, and low-leverage strategies that vary by effectiveness and implementation difficulty, while factoring in the unavoidable potential for human error and health care system complexities. Each strategy includes a description and a list of examples for implementation.

[View ISMP's Strategies for Risk Reduction](#)

## **NABP Executive Committee Member Shares Experience Serving on a State Board of Pharmacy**

---

In an article from the American Society of Health-System Pharmacists (ASHP), three board of pharmacy members share their experiences serving on their boards. NABP Executive Committee member Stacey Ranucci, MBA, RPh, BCGP, CDCES, FASCP, CPEL, discusses her role in helping Rhode Island offer the Uniform MPJE™ to pharmacists. She also supports expanding collaborative practice in Rhode Island. Although the governor appoints pharmacists and technicians to serve on the Rhode Island Board of Pharmacy, Ranucci encourages them to voice their interest in serving on the Board.

[Read ASHP's Article](#)

## **Prior Authorization Bans Did Not Significantly Impact Buprenorphine Treatment Retention Rates**

---

**Researchers** found that state prior-authorization prohibitions did not significantly impact the retention rate of certain patients continuing buprenorphine treatment. According to researchers, prior authorization was considered a barrier that inhibited administration and continuation of buprenorphine treatment for patients. However, when a state passed legislation banning prior authorization for buprenorphine in private insurance, it did not greatly improve long-term treatment outcomes for privately insured patients. In the cross-sectional study, of the 22,946 privately insured patients who began buprenorphine treatment from 2015 to 2022, only 30.4% of patients reached the 180-day mark of treatment. Researchers noted that additional barriers need to be addressed to affect buprenorphine treatment retention.

[Find Out More About the Study](#)

## **Association Mourns the Passing of Oren Peacock, Jr, Past President of NABP**

---

It brings the Association great sadness to announce that former NABP President **Oren M. Peacock, Jr**, passed away on March 10, 2026. In 1962, following his graduation from the University of Texas at Austin College of Pharmacy, Peacock started working as a pharmacist. Over the years, he assumed leadership roles at Eckerd Drug Corporation and CVS, and served as president for two terms on the Texas State Board of Pharmacy.

As an active member of NABP, Peacock participated in numerous committees and task forces. He completed six years on the NABP Executive Committee, including serving as 2007-2008 NABP president. While president of NABP, he focused his initiatives on patient safety, quality outcomes, and peer review. Under his direction, NABP established the Task Force on Continuous Quality Improvement, Peer Review, and Inspecting for Patient Safety.

For his tenacious approach and commitment to the pharmacy profession, Peacock was awarded the Harold W. Pratt Award from the **[National Association of Chain Drug Stores](#)**.

[Honor Oren Peacock's Memory](#)



**HRSA Announces Three New Data Resources for Health Workforce Planning**

The Health Resources and Services Administration (HRSA) has announced three new data resources to assist with health workforce planning: [Health Workforce Explorer](#), [Updated Health Workforce Projections](#), and [Area Health Resources Files](#).  
[Explore Other Health Workforce Data >](#)

*NABP Weekly* is a publication prepared by NABP. Please send any comments, questions, or suggestions about the electronic newsletter to [commdept@nabp.pharmacy](mailto:commdept@nabp.pharmacy). We look forward to receiving your feedback.



National Association of Boards of Pharmacy®

[Unsubscribe](#)

This message was sent to [karin.barron@dc.gov](mailto:karin.barron@dc.gov) from [news@nabp.pharmacy](mailto:news@nabp.pharmacy)

NABP  
National Association of Boards of Pharmacy  
1600 Feehanville Dr  
Mount Prospect, IL 60056